21-Oct-2026 10:36:26
Sun Pharma to Raise ₹10,000 Crore to Refinance Debt Taken for Organon Acquisition
Sun Pharmaceutical Industries plans to raise ₹10,000 crore through rupee-denominated bonds to partly refinance bridge loans taken to fund its proposed $11.75 billion acquisition of US-based Organon. The fundraising includes ₹7,000 crore of bonds carrying an 8.20% coupon and ₹3,000 crore at 8.05%, with maturities in 2031. The move follows board approval for borrowing up to ₹15,000 crore. The bond issue has received a AAA/Stable rating from Crisil, reflecting Sun Pharma’s strong credit profile.